Colitis ulcerative aggravated and Hepatocellular carcinoma

Summary:

Hepatocellular carcinoma is found among people with Colitis ulcerative aggravated, especially for people who are male, 60+ old.

The study analyzes which people have Hepatocellular carcinoma with Colitis ulcerative aggravated. It is created by eHealthMe based on reports of 19 people who have Colitis ulcerative aggravated from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Colitis ulcerative aggravated?

Colitis ulcerative aggravated (inflammation of colon with ulcer) is found to be associated with 1,072 drugs and 326 conditions by eHealthMe. Check the latest studies of Colitis ulcerative aggravated.

What is Hepatocellular carcinoma?

Hepatocellular carcinoma (liver cancer) is found to be associated with 306 drugs and 733 conditions by eHealthMe. Check the latest studies of Hepatocellular carcinoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

19 people who have Colitis Ulcerative Aggravated and Hepatocellular Carcinoma are studied.

Would you have Hepatocellular carcinoma when you have Colitis ulcerative aggravated?

Gender of people who have Colitis Ulcerative Aggravated and experienced Hepatocellular Carcinoma *:

female: 13.33 %
male: 86.67 %

Age of people who have Colitis Ulcerative Aggravated and experienced Hepatocellular Carcinoma *:

Common co-existing conditions for these people *:

Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 3 people, 15.79%
High Blood Cholesterol: 3 people, 15.79%
High Blood Pressure: 2 people, 10.53%
Hypokalemia (low potassium): 2 people, 10.53%
Cirrhosis Alcoholic (chronic disease of the liver marked by degeneration of cells, inflammation, and fibrous thickening of tissue caused by alcoholism): 2 people, 10.53%
Constipation: 2 people, 10.53%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 10.53%
Cardiac Failure Chronic: 2 people, 10.53%
Iron Deficiency Anaemia: 2 people, 10.53%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 5.26%

Common drugs taken by these people *:

Common symptoms for these people *:

Cytomegalovirus Infection: 2 people, 10.53%
Pvt: 2 people, 10.53%
Inflammation: 2 people, 10.53%
Weight Decreased: 1 person, 5.26%
Infusion Related Reaction: 1 person, 5.26%
Drug Effect Decreased: 1 person, 5.26%
Drug Ineffective: 1 person, 5.26%
Fungal Infection: 1 person, 5.26%
Haematochezia (passage of stools containing blood): 1 person, 5.26%
Hepatic Steatosis (fatty liver disease): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Hepatocellular carcinoma?

- Check whether Hepatocellular carcinoma is associated with a drug or a condition

Related publications that referenced our studies

Musri FY, Mutlu H, K?vrak Salim D, Karakurt Ery?lmaz M, ?nal B, Tural D, ?enol Co?kun H, "Sorafenib-induced severe urticaria in a patient with hepatocellular cancer", Journal of Oncology Pharmacy Practice, 2016 Jan .
Musri FY, Mutlu H, K?vrak Salim D, Karakurt Ery?lmaz M, ?nal B, Tural D, ?enol Co?kun H, "Sorafenib-induced severe urticaria in a patient with hepatocellular cancer", Journal of Oncology Pharmacy Practice, 2016 Jan .

Related studies:

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Hepatocellular carcinoma and Colitis ulcerative aggravated, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.